Cover Image
市場調查報告書

滑囊肉瘤:開發平台分析

Synovial Sarcoma - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 321902
出版日期 內容資訊 英文 189 Pages
訂單完成後即時交付
價格
Back to Top
滑囊肉瘤:開發平台分析 Synovial Sarcoma - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 189 Pages
簡介

滑囊肉瘤是生於軟組織的腫瘤,一般分爲雙相型和單相型,由表皮細胞或紡錘細胞所形成。

本報告提供滑囊肉瘤的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

滑囊肉瘤概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • Adaptimmune Therapeutics Plc
  • Advenchen Laboratories, LLC
  • EpiZyme, Inc.
  • Immune Design Corp.
  • Karyopharm Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OncoTherapy Science, Inc.
  • TaKaRa BIO Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AL-3818
  • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology
  • CMB-305
  • everolimus
  • GSK-3377794
  • OTSA-101
  • pembrolizumab
  • selinexor
  • SSTC-104
  • tazemetostat
  • TBI-1301

開發中產品的最新趨勢

開發中止的計劃

產品開發的里程碑

  • 關注的新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9661IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H2 2017, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.

Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 7, 3 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Synovial Sarcoma - Overview 6
  • Synovial Sarcoma - Therapeutics Development 7
  • Pipeline Overview 7
  • Pipeline by Companies 8
  • Pipeline by Universities/Institutes 10
  • Products under Development by Companies 11
  • Products under Development by Universities/Institutes 12
  • Synovial Sarcoma - Therapeutics Assessment 13
  • Assessment by Target 13
  • Assessment by Mechanism of Action 15
  • Assessment by Route of Administration 17
  • Assessment by Molecule Type 19
  • Synovial Sarcoma - Companies Involved in Therapeutics Development 21
  • Adaptimmune Therapeutics Plc 21
  • Advenchen Laboratories LLC 21
  • EpiZyme Inc 22
  • Immune Design Corp 22
  • Immunocore Ltd 23
  • Johnson & Johnson 23
  • Karyopharm Therapeutics Inc 24
  • Merck & Co Inc 24
  • Millennium Pharmaceuticals Inc 25
  • Novartis AG 25
  • Pfizer Inc 26
  • Takara Bio Inc 26
  • Synovial Sarcoma - Drug Profiles 27
  • ACXT-3102 - Drug Profile 27
  • AL-3818 - Drug Profile 28
  • axitinib - Drug Profile 31
  • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 37
  • CMB-305 - Drug Profile 38
  • CUE-102 - Drug Profile 42
  • everolimus - Drug Profile 43
  • Fusion Protein for Oncology - Drug Profile 55
  • GSK-3377794 - Drug Profile 56
  • pembrolizumab - Drug Profile 66
  • quisinostat hydrochloride - Drug Profile 127
  • sapanisertib - Drug Profile 129
  • selinexor - Drug Profile 133
  • SSTC-104 - Drug Profile 155
  • tazemetostat - Drug Profile 156
  • TBI-1301 - Drug Profile 167
  • Synovial Sarcoma - Dormant Projects 168
  • Synovial Sarcoma - Discontinued Products 169
  • Synovial Sarcoma - Product Development Milestones 170
  • Featured News & Press Releases 170
  • Appendix 187
  • Methodology 187
  • Coverage 187
  • Secondary Research 187
  • Primary Research 187
  • Expert Panel Validation 187
  • Contact Us 187
  • Disclaimer 188

List of Tables

  • Number of Products under Development for Synovial Sarcoma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Synovial Sarcoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2017
  • Synovial Sarcoma - Pipeline by Advenchen Laboratories LLC, H2 2017
  • Synovial Sarcoma - Pipeline by EpiZyme Inc, H2 2017
  • Synovial Sarcoma - Pipeline by Immune Design Corp, H2 2017
  • Synovial Sarcoma - Pipeline by Immunocore Ltd, H2 2017
  • Synovial Sarcoma - Pipeline by Johnson & Johnson, H2 2017
  • Synovial Sarcoma - Pipeline by Karyopharm Therapeutics Inc, H2 2017
  • Synovial Sarcoma - Pipeline by Merck & Co Inc, H2 2017
  • Synovial Sarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • Synovial Sarcoma - Pipeline by Novartis AG, H2 2017
  • Synovial Sarcoma - Pipeline by Pfizer Inc, H2 2017
  • Synovial Sarcoma - Pipeline by Takara Bio Inc, H2 2017
  • Synovial Sarcoma - Dormant Projects, H2 2017
  • Synovial Sarcoma - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Synovial Sarcoma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top